Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00

Shares of Precigen, Inc. (NASDAQ:PGEN) have received an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $7.00.

Several equities research analysts recently commented on the stock. JMP Securities decreased their price objective on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Precigen in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Precigen by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock valued at $9,814,000 after acquiring an additional 19,875 shares during the last quarter. Iridian Asset Management LLC CT increased its stake in shares of Precigen by 82.5% during the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after acquiring an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after acquiring an additional 149,829 shares during the last quarter. State Street Corp increased its stake in shares of Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after acquiring an additional 29,253 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 127,467 shares during the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Stock Performance

Shares of NASDAQ PGEN opened at $0.86 on Friday. Precigen has a one year low of $0.77 and a one year high of $1.93. The company’s fifty day moving average is $0.89 and its two-hundred day moving average is $1.20.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.